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Psychopathology, self-esteem, and self-perceived stigma 
were also measured using the Positive and Negative Syn-
drome Scale, the Rosenberg Self-Esteem Scale (SES), the Beck 
Depression Inventory (BDI), the Beck Hopelessness Scale, and 
the Korean version of the Internalized Stigma of Mental Ill-
ness scale (K-ISMI).
Results
- Of the total of 87 participants, 20 (23%) had attempted suicide. 
Patients with a history of suicide attempts had significantly 
higher scores on the BDI (p=0.036) and K-ISMI (p=0.009), and 
significantly lower scores on the SES (p=0.001). Analysis of 
covariance revealed that the SES scores were significantly 
lower in patients with a history of previous suicide attempts 
than in those with no history, after controlling for K-ISMI and 
BDI scores (p = 0.039).
Conclusion
- Low self-esteem appears to represent a psychological dimen-
sion that is closely related to suicide risk. Therefore, clinical 
attention should be paid to the evaluation and enhancement 
of low self-esteem in schizophrenia patients with suicidal-
ity. A longitudinal prospective study is required to ascertain 
whether low self-esteem leads suicide attempts.
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Abstract
Background: Second-generation antipsychotics (SGAs), such 
as olanzapine, are used to treat schizophrenia; however, they 
have minimal benefits for cognitive deficits and cause meta-
bolic side-effects such as obesity [1, 2]. Obesity has been linked 
to increased cognitive impairment [3], complicating the health 
issues of people with schizophrenia. Liraglutide is a synthetic 
glucagon-like peptide-1 (GLP-1) receptor agonist with anti-
obesity and neuroprotective properties [4, 5]; however, whether 
liraglutide can improve cognition during olanzapine treatment 
is unclear. The aim of this study was to examine the effects of 
liraglutide co-treatment on cognition and metabolic parameters 
during olanzapine treatment.
Methods: Sprague-Dawley rats were administered olanzap-
ine (2mg/kg), liraglutide (0.4mg/kg), olanzapine+liraglutide co-
treatment or vehicle (control) (n=12/group) for six weeks. Body 
weight, food intake and locomotor activity were recorded. Novel 
object recognition (NOR) and T-maze tests were conducted to 
examine recognition and working memory. Post-mortem white 
adipose tissue weight was recorded.
Results: Olanzapine caused significant body weight gain and 
increased white adipose tissue mass (p<0.05 vs control), whereas 
liraglutide co-treatment significantly reduced body weight and 
adiposity (p<0.001 vs olanzapine). Olanzapine induced hypolo-
comotion (p<0.001 vs control), whereas liraglutide co-treatment 
significantly increased locomotor activity (p<0.05 vs olanzap-
ine). In the NOR test, olanzapine-treated rats spent significantly 
less time exploring the novel object, and this was significantly 
improved in the liraglutide co-treatment group (p<0.01 vs olan-
zapine). There was no effect of treatment on correct entries in 
the T-maze test (p>0.05 vs control).
Conclusion: This study demonstrates that liraglutide co-treat-
ment can improve locomotor activity, decrease adiposity and 
prevent weight gain side-effects associated with olanzapine 
administration. Liraglutide co-treatment was able to improve 
recognition memory impairment caused by olanzapine treat-
ment; however, it had no effect on working memory. Further 
studies are required to understand the mechanisms underlying 
these changes, and to elucidate whether a link exists between 
olanzapine-induced obesity and liraglutide’s effect on cognition.
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Abstract
Objective: Clozapine is the most effective antipsychotic for 
treatment-resistant schizophrenia, whereas it occurs fatal 
hematopoietic toxicity as agranulocytosis. To elucidate mecha-
nism of hematopoietic toxicity by clozapine, we tried to develop 
the in vitro assay systems using HL-60 cells, and investigated the 
effect on hematopoiesis.
Method: HL-60 cells were differentiated by all-trans retinoic acid 
(ATRA) to three states according hematopoietic process: undif-
ferentiated HL-60 cells, under granulocytic ATRA-differentiation 
and ATRA-differentiated granulocytic cells. Hematopoietic tox-
icity was evaluated by analyzing cell survival, cell proliferation, 
granulocytic differentiation, apoptosis, and necrosis.
Result: In undifferentiated HL-60 cells and ATRA-differentiated 
granulocytic cells, clozapine (50 and 100 µM) and doxorubicin, 
but not olanzapine decreased survival rate. Under granulocytic 
differentiation for 5 days, clozapine, even at 25 µM, decreased 
survival rate without affecting granulocytic differentiation, 
increased caspase activity, and resulted in induction of apop-
tosis rather than necrosis. Lower concentrations of clozapine (1 
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